fbpx JLABS Company News | JLABS

News


Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Lung Cancer Innovation QuickFire Challenge

Jlab_Quickfire-2018-06-12
lung cancer
Challenge ended

$750,000 (¥4.7M) in Grants + Residency + Mentoring

Surgical Oncology
Therapeutics

                        点击这里阅读中文

Awardees

Lung%20Cancer%20Innovation%20QFC%20Awardees.png

 

DNX Biopharmaceuticals

 

DNX Bio is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

 

Hawkeye Bio

 

Hawkeye Bio was launched in 2018 in California to commercialize novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

 

NE Scientific

 

NE Scientific is a Boston-based startup company developing a surgical guidance software for supporting physicians in targeting tissues during the percutaneous ablation of liver and lung tumors. The Accublate (TM) guidance software simulates in real-time the physics taking place during the ablation and determines the ablation volume in a patient-specific way. This information is generated intraoperatively and overlaid to CT images of the patient, helping the physician in achieving a complete treatment of all malignant tissues.

[1]HawkeyeBio.com, 2019

The Challenge

Image Paragraph

The average person breathes in 432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen.  To that end, it is essential that we protect our lungs.  

Is there a way to cleanse the lungs after exposure to carcinogens much like a toothbrush cleanses the mouth after eating? Is there a way to shield the lungs from carcinogens much like sunscreen shields us from damaging UV exposure?  These are a few of the provocative ideas Johnson & Johnson Innovation hopes to trigger through the Lung Cancer Innovation QuickFire Challenge. 

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year.  Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth.  Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.  

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health.  How do we leverage the totality of science and technology to achieve comprehensive lung health -  to ultimately prevent, intercept and cure lung cancer?

Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Reward

Up to $750,000 (¥4,775,850) in total grants 
  • 1 year residency at JLABS @ Shanghai (Optional)
  • Mentoring & coaching from experts from Johnson & Johnson Innovation and/or its affiliates

Areas of Interest

We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • Interception: Arrest lung cancer as it develops, prior to clinical onset
  • Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health

Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.  

We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to: 

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation 
  • To develop approaches to measure the exposure to and biological effect from respiratory carcinogens
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • To develop new treatments or treatment modalities for the cure of lung cancer

Approaches should include the following areas:

  • Pharmaceuticals
  • Consumer products
  • Medical devices
  • Global public health
  • Health technologies
  • Cross-sector initiatives – an integration of one or more the aforementioned areas of focus 

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

Timeline

June 14, 2018 (China Time)
Applications Open
September 21, 2018 (China Time)
Submission Deadline
Spring 2019
Winner Announcement at JLABS @ Shanghai Launch

Apply Now


Don’t miss the deadline

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

FAQs

 

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 

Q: Is residency at JLABS @ Shanghai required?

A: No. Residency is encouraged but optional.

 

Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?

A: No. We are seeking innovations globally.

 

Q: For prizes involving residency at JLABS, what does that entail and for how many people?

A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.

 

Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

 

Q: Will JLABS pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: Apply at https://jlabs.jnjinnovation.com/form/lung-qfc-apply. You are able to save your work and log back in to finish at a later time if needed.

About Johnson and Johnson Innovation, JLABS

Picture1.png

 

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit jlabs.jnjinnovation.com.

About Johnson & Johnson (China) Investment Ltd

Picture1_0.png

 

 

 

 

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。

 

 


 

First 1000 Days QuickFire Challenge

first 1000 days
Challenge ended

Up to $250,000 + Mentorship

Global Public Health
Pharmaceuticals

Bloomlife%20Logo.png

Bloomlife's vision is to design the future of prenatal care to improve the health of moms and babies.  CEO Eric Dy explains, “Through the most advanced combination of technology, medical expertise, and data science, we are bringing long overdue innovation to better understand pregnancy and its complications to improve birth outcomes for every mom and child.”

Read more here.

The Challenge

1000 Days

A first heartbeat. First smile. First step. The First 1000 Days of life are the most critical in human development. This unique window immensely impacts the trajectory of health. 

As the overall approach to healthcare transitions away from treating chronic disease after it manifests and moves towards preventing disease before it begins, Janssen Research & Development, LLC and Johnson & Johnson Innovation, JLABS are calling on innovators to turn their attention to those crucial first years for mom and baby.  In the First 1000 Days QuickFire Challenge, we’re seeking game-changing ideas, with an emphasis on health technologies, which will lead to the prevention and interception of childhood disease and disorders at the earliest stages.

Submit solutions to impact the First 1000 Days to help every mother and child get their healthiest start possible.

Awards

Up to $250,000 in Grants
  • Mentoring from experts at Johnson & Johnson Innovation

Areas of Interest

The prenatal period of in-utero fetal development and programming and the First 1000 Days of life set a trajectory for health and a susceptibility for disease that may occur either in the childhood and adult years.

We’re interested in submissions addressing disease prevention and interception throughout the complete spectrum of the First 1000 Days.

Due to the exponential uptake of technologies such as smart phones and wearables, there is a growing opportunity to amass a myriad of types of data from the individual, family, and community to better detect disease risk. An emphasis on innovations incorporating health technologies will be considered.

 

Specific areas of focus include:

 

Healthy Development of the Vulnerable Child 

Factors such as nutrition, environment and quality care are important for healthy growth and thriving. The vulnerable child can have health disparities that lead to differences in mortality and disease risk related to behaviors, access to health care and social determinants of health. 

Priorities:

  • Approaches to predict trajectory for health/disease

  • Smoking Cessation/smoking and nicotine exposure

  • Optimal Sleep: Mother and Infant

  • Stress and Mental Health, including anxiety, depression, and mood disorders

  • Breast milk quality 

 

Childhood Food Allergy and Allergic Disease

The incidence and prevalence of food allergy, eczema, hay fever, and asthma have increased dramatically in children in recent decades.  According to FoodAllergy.org, 1 in 13 children in the United States has a food allergy, and there is an increased prevalence in both developed and developing countries in recent decades.    

Priorities include: 

  • Novel approaches to detect risk of food allergy and/or atopy (e.g. eczema)

  • Novel decision support tools for food allergy and/or atopy

  • Novel approaches to prevent or intercept food allergy and/or atopy prior to its symptomatic state

 

Preterm birth

The world’s number one killer of young children is preterm birth (prematurity), with over 1 million children dying annually from direct complications of birth before completing 37 weeks of pregnancy, affecting 1 in 10 pregnancies both in the United States and worldwide, and increasing in incidence globally. Beyond direct complications, preterm birth is also associated with significant long-term morbidity and increases susceptibility for multiple childhood and adult diseases. Among African-American mothers, the rate of preterm birth is 50% higher than the rate among white mothers in the United States.

Priorities include:

  • Novel approaches for earlier detection of risk of preterm birth

  • Novel approaches to prevent microbiome or infection-related preterm birth 

  • Novel approaches to detect and prevent stress-induced preterm birth arising from maternal health behaviors including anxiety and depression, non-optimal sleep duration and quality, smoking, obesity and socio-demographic factors

  • Novel devices to prevent preterm birth

 

Childhood Obesity

Childhood obesity is an increasing public health issue. Worldwide ~ 340 million children are obese. It has been projected that ~60% of current two-year old children in the US will be obese by age 35 years. Childhood obesity predisposes to childhood-onset type 2 diabetes and adult obesity, which is associated with significant morbidity and mortality.  

The First 1000 Days is recognized as a critical period for the development of childhood obesity that is conferred by genetics, epigenetics, and environment by influencing expression of specific genes regulating metabolism, immune responses, and adipogenesis.

Priorities include:

  • Improved detection of risk of childhood obesity

  • Preconception, first trimester, neonatal/infant interventions for prevention or interception of childhood obesity

 

Autism Spectrum Disorder (ASD)

ASD is a complex neurodevelopmental disorder affecting communication and behavior with symptoms usually beginning in early childhood. CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network estimates that about 1 in 59 children are identified with autism spectrum disorder in the United States and occurs in all racial, ethnic, and socioeconomic groups. Diagnosis is often delayed until after age 4 years though symptoms are often present in the first year of life and a diagnosis can be made usually by two years of age.  Early detection and diagnosis allows earlier intervention, which can greatly improve a child’s development.7

Priorities include:  

  • Earlier detection of ASD

  • Population screening for detection of ASD

Please keep in mind that no idea is too big nor too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. 

 

 

-------------------------------------

Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology? Physiol Rev. 2014;94:1027-76.

Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology? Physiol Rev. 2014;94:1027-76.

Child Health Disparities: What Can a Clinician Do? Cheng TL, Emmanuel MA, Levy DJ, Jenkins RR. Pediatrics. 2015 Nov;136(5):961-8. doi: 10.1542/peds.2014-4126

RubensCE, Sadovsky Y, Muglia L, Gravett MG, Lackritz E, Gravett C. Prevention of preterm birth: harnessing science to address the global epidemic.Sci Transl Med. 2014;262. Epub 2014.
 

Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes.Science. 2014;345:760-5

https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm

Lancet 2017;390:2627-42

N Engl J Med 2017; 377:2145-2153

Nestle Nutr Inst Workshop Ser. 2017;87:183-196.

Lancet. 2018 Aug 2. pii: S0140-6736

Application Process

Each baby has his or her own unique risk factor determined by both genetics and environmental risks. Socioeconomic factors may further increase risk and disease susceptibility. We’re specifically interested in technologies that monitor, assess, and provide insights to improve a mother and baby’s unique risk profile.

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Novelty
  • Potential Impact
  • Feasibility/Practicality
  • Perceived Commercialization Potential
  • When applicable, use of health technologies to best monitor, analyze, and identify opportunities for disease interception during the first 1000 days.

 

 

-------------------------------------------

 

Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology?Physiol Rev. 2014;94:1027-76.

Child Health Disparities: What Can a Clinician Do? Cheng TL, Emmanuel MA, Levy DJ, Jenkins RR.

Pediatrics. 2015 Nov;136(5):961-8. doi: 10.1542/peds.2014-4126

 

Timeline

August 28, 2018
Applications Open
November 2, 2018
Deadline
Q1 2019
Winner Announced

Why this challenge matters to us

Through its World Without Disease Accelerator group, Janssen is working toward a vision of creating a world without disease. By bringing together distinct enabling capabilities in areas including the microbiome, immunosciences, predictive analytics and behavioral science, a team of experts is focused on seeding and accelerating transformative growth opportunities to catalyze a paradigm shift in health care through prevention, interception and cure strategies and solutions. Science indicates that some of these root causes may be initiated during the First 1000 Days.

Apply Now

Submit your idea today!


Don’t miss the deadline

FAQs

What if I’m having trouble accessing the portal/website?

Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

Can I submit supporting documents (for example a video) as part of my application? 

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP (Intellectual Property)?

As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

What kind of science / technology is appropriate for the Challenges? 

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

Who is eligible to apply?

Each Challenge has its own terms & conditions that can be found prior to filling out the application.

What are the specific criteria for application?

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities

Who can I contact if I have questions about the Challenge or the application process?

Please contact [email protected] with any questions

Where do I apply? And do I have to complete the application in one sitting?

You can setup an account at https://jnj-quickfire.smapply.io. You are able to save your work and log back in to finish at a later time if needed.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

Picture1_1.png

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com . Follow us at Twitter.com/JanssenGlobal.

 

 

About Johnson & Johnson Innovation, JLABS

johnson-johnson-jlabs-7x4.jpg

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto, and in NYC in collaboration with the New York Genome Center. Recently, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe and JLABS @ Shanghai will open in 2019.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

PExA

PExA AB is a Swedish start-up company that has developed a breakthrough technology enabling
collection of biomaterial from the small airways with potential in discovery of respiratory biomarkers

Focus area
Diagnostics

JLABS @ NYC QuickFire Challenge

JLABS at New York City
JLABS @ NYC QuickFire Challenge
Challenge ended

Residency at JLABS @ NYC

Pharmaceuticals
Image paragraph

The Challenge

In honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

Rewards and benefits

Space at JLABS @ NYC

Areas of interest

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:

  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics

Frequently Asked Questions

What if I’m having trouble accessing the portal/website?

Make sure your browser is up to date and accepting cookies. You can contact customer service at https://jnjawards.fluidreview.com/helpdesk/contact/ if you are having technical difficulties as well.

For prizes involving space at JLABS, what does that entail and for how many people?

For challenges involving space at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees we can rent out an additional space.

For prizes involving space at JLABS, are there any expenses not covered by JLABS?

Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

Will JLABS pay for my living costs, relocation or visas?

No, any additional fees and paperwork are up to the winner.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP?

As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

What kind of science / technology is appropriate for the Challenges?

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering.

Who is eligible to apply?

Each Challenge has it’s own terms & conditions that can be found prior to filling out the application.

Who can I contact if I have questions about the Challenges or the application process?

Please contact [email protected] with any questions. 

Where do I apply? And do I have to complete the application in one sitting?

You can setup an account at http:// jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

Winners

lab11.jpg

Lab11 Therapeutics LLC: Lab11 Therapeutics LLC is a startup biotech company spun out of the Icahn School of Medicine at Mount Sinai. The company is developing host-targeting small molecule broad spectrum anti-viral drugs, with the first indication being anti-influenza A virus (IAV) drugs.

Manhattan%20bio.png

Manhattan Biosolutions: Manhattan BioSolutions is a biotech start-up focused on the discovery and development of the next-generation immunotherapy for the treatment or potential prevention of cancer. Their proprietary technology platforms are aimed to enhance or augment the natural ability of the immune system to recognize cancer as foreign and defend the body against malignancies. 

sapience_1.png

Sapience Therapeutics, Inc.: Sapience Therapeutics is a preclinical-stage biotechnology company seeking to develop novel treatment approaches for oncology indications with high unmet need. Their initial goal is to develop a first-in-class treatment that targets the ATF5 transcription pathway, which holds the potential to treat many cancers, including AML, GBM, medulloblastoma, neuroblastoma, breast cancer, and more.

MobileSense.jpg

Mobile Sense Technologies, Inc.: Mobile Sense™ is building foundational technology that enables this transformation through off-the-chest wearables for long term management of cardiac arrhythmias. Embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provide high fidelity ECG and PPG recordings. 

Bugs, Drugs & Beyond QuickFire Challenge

Bugs, Drugs & Beyond QuickFire Challenge
Challenge ended

Residency at JLABS

Pharmaceuticals

The Challenge

Are you a new game-changing early-stage microbiome company? The Bugs, Drugs & Beyond QuickFire Challenge is officially open! We encourage innovators with promising ideas or research with the potential to impact patients-- to apply now.  The winner will be awarded one year of residency at the state-of-the-art JLABS @ TMC in Houston and be announced at the end of the event on Mar. 1st.

Timeline

PST
Deadline to apply
PST
Announcement of winners

Advance Queensland Johnson & Johnson Innovation QuickFire Challenge

Advance Queensland Johnson & Johnson Innovation QuickFire Challenge
Challenge ended

Funding up to AUS $ 100,000

Pharmaceuticals

Winners

Image paragraph

Developing a prototype device for the early detection of heart damage, which is crucial to saving patients’ lives. The device is based on Atomo Diagnostics' existing point-of-care technology and will utilise cardiac markers developed by Brisbane-based Anteo Technologies. The proposed technology offers up the possibility of providing an easy-to-use, accurate and rapid lowcost diagnostic test, with the potential to offer an affordable and widely deployable alternative to expensive hardware systems.

Image paragraph

Using nanotechnology Eikonic has identified a chemical compound that targets the class of bacteria responsible for gum disease and tooth decay. The company is hopeful that it can develop a potential preventive topical application that can be applied daily and is easy to use, avoiding the need for complex, costly and invasive conventional procedures.

Image paragraph

Pre-clinical testing of a chemical compound called antroquinonol, which offers potential as a possible treatment for Alzheimer's disease. Derived from a mushroom commonly used in Chinese traditional medicine, antroquinonol has the possibility of tackling one of the biggest challenges in treating Alzheimer’s – crossing the blood-brain barrier. The company will use the prize money to prepare the groundwork for a pilot study of the compound with early-stage Alzheimer’s patients.

Advance Queensland QuickFire Challenge

The Queensland State Government in collaboration with Johnson & Johnson Innovation have launched the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge to award up to three new game-changing early-stage human healthcare inventions with an award of AUD 100,000 each and access to mentorship and coaching from J&J staff.

Artificial Intelligence for Drug Discovery QuickFire Challenge

JLABS - Artificial Intelligence for Drug Discovery QuickFire Challenge
Artificial Intelligence for Drug Discovery QuickFire Challenge
Challenge ended

Up to $100,000 USD*

Immunology

Winners

 

A2A

A2A Pharmaceuticals: At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.  

 

Envisagenics

Envisagenics: Cloud-based drug-target discovery platform (SpliceCore) using AI to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. 

 

Traceryo

Tracery Ophthalmics: Tracery is a clinical stage ocular imaging and health tech company focused on Age Relate Macular Degeneration and blinding eye disease.  

The Challenge

Image paragraph

At Johnson & Johnson Innovation and Janssen Research & Development our goal is to improve the health and wellness of people around the world. Artificial intelligence (AI) poses unlimited opportunity for us to make a transformative impact on patients. Whether it be through new drug combinations, improved medical diagnostics, better accuracy in personalized medicine, or many other benefits - AI could save scientists valuable research time and bring new treatments to patients more quickly. To that end, Johnson & Johnson Innovation is looking to award up to $100,000 in grants, one year of JLABS residency & mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are using artificial intelligence to advance healthcare.

Rewards and benefits

$100,000*
  • *Up to $100,000 USD in grants for multiple winners
  • Residency at an available JLABS location
  • Mentoring & coaching from J&J experts

QuickFire Challenge innovation focus areas

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using artificial intelligence to advance drug discovery & development in any of these areas:

  • Oncology & Immuno-oncology
  • Immunology
  • Cardiovascular & Metabolism
  • Infectious Diseases & Vaccines
  • Neuroscience
  • Pulmonary Hypertension
  • Rare Diseases
  • Pre-clinical safety studies
  • Systems pharmacology
  • Clinical trials
  • Precision Medicine
  • Chemo-informatics
  • In silico compound & safety profiling
  • Real world evidence

Timeline

EST
Applications Open
EST
Submission Deadline
EST
Judging Commences
EST
Finalists Pitch at JLABS @ Toronto and Winners are Announced 

Application process

A panel of reviewers and judges will evaluate submissions based  on their ability to meet the following criteria:

  • Scientific/Technical Excellence
  • Novelty
  • Feasibility/Practicality
  • Perceived commercialization potential
  • Clarity on milestones and deliverables
  • Quality of Team and Resources
  • Plan for use of funds


Deadline to apply is October 27th, 2017
Winner(s) will be announced in December

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at Twitter.com/JanssenGlobal.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.


About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

Can We Teach Old Compounds New Tricks?

Different diseases can share a biological pathway and that is why studying compounds initially developed for one disease as a potential treatment against a different one may improve our understanding of a range of diseases and offer the chance to develop more effective treatments.
This idea was a key factor for the Neuroscience team at Janssen in its decision to enter, in collaboration with Johnson & Johnson Innovation and six other pharmaceutical companies, into a collaborative program  with the British Medical Research Council (MRC) that offers UK-based researchers the opportunity to access certain compounds  that are not in active development.
We are pleased to participate in this academic-industry collaboration aimed at speeding the identification of new therapeutics for patients. 
Under the program, deprioritized compounds or biologics can be tested by an academic group in a study or a series of studies leading up to a clinical proof of concept.  Often the academic group will test the compound in a different indication than the one the pharmaceutical company was testing.   
We laid the groundwork for participation in this type of program a few years ago when we collaborated with the National Center for Advancing Translational Sciences (NCATS) at the NIH. The first of these partnerships was with professors at Virginia Commonwealth University and University of Pittsburgh and aimed to test a Janssen compound for its potential benefits in smoking cessation and cognition.  Preclinical testing was performed by the academic group, laying the groundwork for clinical proof-of-concept. 
The project emerged from an academic crowdsourcing effort by the NCATS/NIH.  Fifty-eight candidate compounds were listed on a website and academic teams reviewed and made a case, in the form of an application for a contract, for each new POC effort.  Nearly 150 initial applications were submitted, and eventually a handful of proposals were selected for funding by the NIH.  In a second round of proposals, Janssen submitted compounds from its Neuroscience and Immunology teams.
Now, through the MRC program we are making available certain compounds from our Neuroscience portfolio for use in potential new studies at academic centers in the UK to improve the understanding of brain and other disorders, with the potential to help develop effective new treatments. 
The value created by our teams in advancing new medicines to the clinical stages is immeasurable.  Through programs like this we can leverage the excellent work undertaken by the discovery and early development teams at Janssen before a program was deprioritized. 
It is a reality of our business that not all programs move forward, but through repositioning collaborations we can facilitate further opportunities to test new proof-of-concept ideas that could benefit patients with these valuable resources.
This program is a great example of our commitment to open innovation, advancing great science and sharing resources to speed the development of new medicines for urgent healthcare needs.
Type
Articles

Accelerating Progress on Dementia Research

Alzheimer’s disease is a looming global epidemic impacting millions of people and their families around the world.  As a neuroscientist, I’ve seen first hand just how complex and elusive the development of better solutions to this devastating disease can be. 
Despite the challenges, our company has a long-standing legacy in neuroscience research and mental health care and is committed to advancing research into new approaches to detect, treat and ultimately prevent this disease.   So we are particularly pleased to be participating in the UK Dementias Research Platform (UKDP) - a large public-private partnership led by the Medical Research Council to accelerate progress in dementias research around a single robust research enterprise.
The UKDP leverages existing strengths across the industry and brings together six industry and eight leading academic institutions to collaborate in the areas of neuroscience, population science and clinical research.  The UKDP seeks to aggregate knowledge from existing cohorts of subjects, develop a registry and establish a foundation that would enable a significant drive towards more effective clinical trial experimentation.
Under the collaboration more than 20 existing cohorts of nearly two million subjects will be used to identify cognitive, genetic, physiological and imaging markers whose changes are associated with early stages of dementia before diagnosis. In addition, another key goal  is to establish a 10 thousand subject pre-dementia readiness cohort to allow for experimental medicine studies.
In this way, we bring together a large network under one initiative that can capitalize on diverse expertise. 
Our approach to addressing Alzheimer’s disease includes internal research, external innovation, and engagement in a broad network of collaborations such as the UKDP.  Delivering innovative new solutions will require not only a deep understanding of the biology of the disease, but also a commitment to deep collaboration with individuals, companies, academia, governments and patient groups who are similarly committed to these goals.
Type
Articles

Putting Patients First – No Time to Waste

At Johnson & Johnson Innovation we are always seeking to address significant unmet need by applying the best science - no matter where it resides – to develop new medicines.  When we see exciting science, we go for it – establishing new relationships and when the fit is right, joining forces in the hope of positively impacting lives.
              And while collaborations in the pharmaceutical industry have a reputation of taking months to execute, we recently set ourselves a new and worthy benchmark for nimbleness and speed.
              In hepatitis C, patients have faced long odds to achieve a cure from this devastating disease.  At Janssen, we have worked and collaborated with other companies for more than a decade to make a meaningful difference for those affected by the hepatitis C virus (HCV).  These efforts have yielded great advancements in the treatment of HCV. 
              Janssen contributed significantly to these advances, through several collaborations with companies like Medivir AB and Vertex Pharmaceuticals Inc., and this has resulted in over 200,000 patients having an opportunity for HCV cure. 
              Not satisfied with our efforts Janssen Pharmaceuticals Inc. recently concluded, in record time, an agreement with Achillion Pharmaceuticals Inc. for an exclusive worldwide license and collaboration arrangement, to develop and, upon regulatory approval, commercialize one or more of Achillion’s lead HCV assets.  
              In April, we met and discussed the idea of working together.  Grounded in the scientific evidence and driven by a strong belief that we could positively impact millions of patients’ lives our two companies saw no time to waste.  Almost immediately we entered into extensive discussions which culminated in the collaboration announced on May 19. Today, in recognition of World Hepatitis Day, we celebrate this deal and the hope it brings to even more advances in the future.
              When quick, nimble deals are strived for, the timeline in developing the science is accelerated, along with the possibility for breakthroughs that have the potential to benefit patients. This collaboration illustrates how excellent team work and cooperation from two companies who put patients at the center can work quickly and impeccably to accomplish and exceed goals.
              This new, transformative partnership, coupled with our recent acquisition of Alios Biopharma in November 2014, has the potential to help those who are still burdened with HCV across the globe.   With 150 million patients who could possibly benefit - the potential of the science and the nature of this deals’ execution demonstrates one thing - speed is of the essence.

Author: Marianne De Backer, Vice President, Johnson & Johnson Innovation- Janssen Business Development

Type
Articles

What’s the Deal with Patrick Verheyen?

Today, more than ever, our commitment to delivering innovative healthcare products to patients and consumers means that we must seek and support innovation globally. We are fortunate to live in a time when advances in science and technology continue to enable truly transformational healthcare products that help us to live longer, happier lives. But diseases we are seeking to tackle – like Alzheimer’s disease, diabetes, and cancer – are complex, and that is why having a large global network that connects the best scientific minds, is essential to drive breakthrough new products. This is true whether you are working at the earliest stages of basic research or the final stages of clinical drug development. 
We know that a great idea can come from anywhere. Over the past 2 years, I’ve had the honor of helping to establish Johnson & Johnson Innovation and our regional Innovation Centers. Having led the London Innovation Centre, I saw first-hand, the richness and diversity of the European life science ecosystem. The collaborations we established and continue to advance were uncovered in part through a strategy of proximity – having our scientific and business experts on the ground and working on a day-to-day basis with our external collaborators to help nurture and advance incredibly exciting science that we hope will enable new products.
We earn and maintain the privilege of working with our collaborators by being flexible, transparent and accountable. It’s this approach that I’m excited to bring to my new role as Global Head of Janssen Business Development. While my team and I work with big pharma partners and established biotechs and in general look for later stage licensing and acquisition opportunities than our innovation center colleagues, I believe the principles of flexibility and creativity and spirit of collaboration are the same. 
So for me, it’s not about the deal.  We want to give breakthrough new products ideas the support they need and every advantage to succeed. We depend on partnerships to realize our vision of eliminating disease for people around the world. Achieving this means working beyond the deal to ensuring the right team, with the right incentive and commitment is in place and that access to scientific insights and expertise open new possibilities for patients.

By Patrick Verheyen, Global Head, Johnson & Johnson Innovation - Janssen Business Development
 

Type
Articles

A Great Idea Can Come From Anywhere

Innovation is nothing new to the Nordic region, making the new alliance between the Johnson & Johnson Innovation and Karolinska Institutet an intuitive match. As part of this collaboration, Johnson & Johnson Innovation’s London team has established a life science hub at Karolinska Institutet to accelerate and progress the translation of promising science by providing emerging life science companies with investment and access to a wide range of resources and expertise across the Johnson & Johnson Family of Companies.
Karolinska Institutet was founded in 1810 as an "academy for the training of skilled army surgeons." Today it is one of the world’s leading medical universities and the home of the Nobel Prize in Physiology or Medicine. Karolinska Institutet has strategically positioned itself at the front line of exploration in several scientific fields and also has existing external collaborations with universities and companies worldwide.  
Even before this alliance was announced, Johnson & Johnson Innovation had initiated an exciting collaboration with researchers at Karolinska Institutet towards disease interception in Rheumatoid Arthritis (RA).  This collaboration focuses on increasing our understanding of disease initiation and progression and generating early biomarkers of disease and new drug targets.
Johnson & Johnson Innovation focuses on accelerating early-stage science worldwide.  We do this by establishing collaborations with entrepreneurs and innovators around the world and providing them access to resources and expertise from across the Johnson & Johnson Family of Companies. Proximity – being on the ground to engage in the local life science ecosystem - is a key enabler of this strategy. This new collaboration will establish an office at Karolinska Institutet’s and a heightened presence in the region. Karolinska Institutet will act as a platform for exciting opportunities stemming from Karolinska Institutet as well as throughout the Nordic region.
The alliance calls for knowledge exchange, establishment of scouting programs, investment to advance ideas towards proof of concept, and seed financing for new company formation.  
This collaboration is a great example of an emerging type of relationship between academia and industry; a relationship that allows for a broad, flexible and ever evolving approach toward innovation. By establishing a dynamic interface between our organizations we can combine and leverage our respective expertise to advance new ideas, technologies, and healthcare products with the potential to positively impact human health in the Nordic region and beyond.
Type
Articles